We are live on ! Find out more
ORKA

Oruka Therapeutics
ORKA

16 hedge funds and large institutions have $16.3M invested in Oruka Therapeutics in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.29% more ownership

Funds ownership: 0% → 0.29% (+0.29%)

3% less capital invested

Capital invested by funds: $16.8M → $16.3M (-$498K)

6% less funds holding

Funds holding: 17 → 16 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Holders
16
Holders Change
-1
Holders Change %
-5.88%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$47.4K
2
Deutsche Bank
Deutsche Bank
Germany
+$20.2K
3
UBS Group
UBS Group
Switzerland
+$2.66K

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$713K
2
RA
Royce & Associates
New York
-$363K
3
Millennium Management
Millennium Management
New York
-$30K
4
Bank of America
Bank of America
North Carolina
-$5.32K
5
Goldman Sachs
Goldman Sachs
New York
-$4.26K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$4.16M – – –
Franklin Resources
2
Franklin Resources
California
$3.47M – – –
VMI
3
VHCP Management II
New York
$3.08M – – –
TCM
4
Tekla Capital Management
Massachusetts
$2.31M – – –
VM
5
VHCP Management
New York
$1.32M – – –
RCM
6
RA Capital Management
Massachusetts
$662K -$713K -1,340 -55%
ACP
7
Aveo Capital Partners
Colorado
$661K +$571K +1,073 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$347K – – –
Deutsche Bank
9
Deutsche Bank
Germany
$131K +$20.2K +38 +22%
Goldman Sachs
10
Goldman Sachs
New York
$58K -$4.26K -8 -8%
Renaissance Technologies
11
Renaissance Technologies
New York
$55K +$47.4K +89 New
BFA
12
BlackRock Fund Advisors
California
$43K – – –
Cambridge Investment Research Advisors
13
Cambridge Investment Research Advisors
Iowa
$30K – – –
BIM
14
BlackRock Investment Management
Delaware
$3K – – –
UBS Group
15
UBS Group
Switzerland
$3K +$2.66K +5 New
Bank of America
16
Bank of America
North Carolina
$2K -$5.32K -10 -77%
RA
17
Royce & Associates
New York
– -$363K -582 Closed
Millennium Management
18
Millennium Management
New York
– -$30K -49 Closed
TRCT
19
Tower Research Capital (TRC)
New York
– -$1K -2 Closed
Creative Planning
20
Creative Planning
Kansas
– -$532 -1 Closed

ORKA Hedge Fund Activity: Q4 2016 in Review

16 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q4 2016, worth a combined $16.3M — down 3% from $16.8M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ORKA and 3 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 1 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $47.4K. The largest seller was RA Capital Management, cutting an estimated $713K.

  • 16 institutional investors held Oruka Therapeutics (ORKA) as of Q4 2016, down from 17 in Q3 2016.
  • Funds reported $16.3M of Oruka Therapeutics stock for Q4 2016, down 3% quarter-over-quarter.
  • 3 funds opened new Oruka Therapeutics positions in Q4 2016 and 4 closed out, a net change of -1 holder.
  • The largest Oruka Therapeutics buyer in Q4 2016 was Renaissance Technologies, an estimated $47.4K added.
  • The largest Oruka Therapeutics seller in Q4 2016 was RA Capital Management, an estimated $713K sold.

Based on aggregated 13F filings for Q4 2016.